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OBJECTIVES: Lower urinary tract symptoms (LUTS)
such as detrusor instability or urinary retention strongly
impacts quality of life, involving economical aspects and
social living. The aim of our investigation is to record
changes in hospitalizations, Urological, and general prac-
titioner visits before and after sacral nerve stimulation
therapy. Expenses for pads, catheters, and drugs are also
investigated. METHODS: From February 2000 to Sep-
tember 2002 we enrolled 62 patients in the economic
session of the Italian Sacral Nerve Modulation Registry
(mean age 50 years old, from 22 to 70). Economic data
was recorded in order to compare costs with clinical
results of sacral nerve modulation therapy in patients
with LUTS. In this group 41 were incontinent patients
(61% female) mean age 53; 21 patients (71% female)
mean age 46 had urinary retention. RESULTS: We per-
formed a quarterly analysis, comparing the baseline data
to the last follow up available (12 month). Visits to the
general practitioner decreased from 1.1 to 0.05 (p < 0.01),
visits to the urologist did not change signiﬁcantly from
baseline (1.5 to 1.2). Diagnostic tests decreased from 2 to
0.8 (p < 0.01). In the use of pads we observed a major
change from 2.1/day (3 months expenses per patient of
€120.96) to 0.5 (3 months expenses per patient of €28.8)
(p = 0.08); For urinary retention the use of catheters
decreased from 1.1 baseline (3 months expenses per
patient of €178.2) to 0.1 at 12 months (3 months
expenses per patient of €16.2) (p = 0.09). Drug con-
sumption decreased signiﬁcantly (p < 0.05) from €47.24
to €10.53. CONCLUSIONS: The reduction in daily con-
sumption of pads and catheters (which is the major cost-
driver of urinary disorders), but also the reduction of
costs due to general practitioner visits, diagnostic tests,
and drug consumption are signiﬁcantly changed.
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OBJECTIVES: An important complication of Benign
Prostate Hyperplasia, a bothersome condition of ageing
men, is Acute Urinary Retention (AUR). This condition
needs acute catheterisation and is a predisposing factor
for surgery. Removal of the catheter is only possible in a
minority of patients if no drugs are used. Alpha-blockers
may increase the success rate of removing the catheter and
decrease the need for future surgery. This study assessed
the costs of treating patients with AUR with alfuzosin,
watchful waiting or immediate prostatectomy in Belgium.
METHODS: According to a randomised controlled trial
(ALFAUR study) removing the catheter is successful in
47.9% of patients treated with watchful waiting and
61.9% of those treated with 3 days of alfuzosin (cost
€0.92 per day). Based on the treatment path and imme-
diate clinical outcome in the ALFAUR study, a medical
decision model to compare the costs and health effects of
the three possible strategies was built in Excel MS 2000,
whereby follow-up results were obtained from epidemio-
logical data. The cost of events was based on a patient
chart review (n = 63) in patients with a ﬁrst episode of
AUR and conducted from the health care payer’s per-
spective. The time horizon of the model was 6 months.
RESULTS: At 6 months, 32.3% of patients who initially
voided successfully were re-hospitalised to undergo a
prostatectomy. Six-month cost of patients treated with
alfuzosin, watchful waiting and immediate prostatectomy
were respectively €4175, €4758, and €6036. These results
were robust under a wide range of plausible assumptions.
CONCLUSIONS: Based on the current available clinical
data, a very small investment (3 units of alfuzosin) can
lead to important savings for the public health care payer
by treating all patients hospitalised with AUR with alfu-
zosin. Further research on utilities in these patients is
expected to strengthen this conclusion.
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AVF are recommended over catheters because they have
lower morbidity and costs. OBJECTIVES: The aim was
to evaluate the cost effectiveness according to patient’s
survival and the difference caused by the delay of an ade-
quate AVF implementation when starting periodical
haemodialysis PHD. Pts included: all pts but 19pts start-
ing PHD during 1996–2000 (n = 133). One deﬁned three
groups of pts according to the time in having deﬁnitive
AVF: Group 1 (G1) having an adequate functioning AVF
before initiating PHD and it lasting at least three months
(53%); G2 not having a AVF at the beginning of PHD,
but in the ﬁrst 3 months of the entrance in PHD (25%)
and G3 being using catheters for more than 3 months
(22%). Studied resources cost: the AVF execution and
patient’s medical care, the mean hospital admissions (HA)
and their mean length stay (LS), catheter cost and time of
personnel as direct and indirect costs. Beneﬁts were cal-
culated evaluating patient’s survival and drugs were not
included by the complexity and patient’s diversity.
RESULTS: G1 were younger than G2 and G3, had lower
infections and less attributable death, lower CI, less HA
and LS. Total AVF costs were estimated in €3071. It could
have been avoided about 11–15% because of catheter
infections and 12 attributed deaths. So mean beneﬁts
could have been €5400 respect to G2 and €6860 to G3.
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Keeping in mind that the beneﬁts were measured by sur-
vival groups, the cost effectiveness was: €57/month of life
for G1, 181 for G2, and 222 for G3. CONCLUSIONS:
not having an adequate vascular access in order to start
PHD, causes not only an important decrease of survival
but more indirect costs as less beneﬁt too.
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OBJECTIVES: The costs associated with kidney trans-
plantation are substantial, not only because of trans-
plantation surgery but also due to the life-long need for
immunosuppressive medication to prevent graft rejection.
We analyzed the clinical and economic consequences 
of the use of the two baseline immunosuppressants,
tacrolimus (Tac), and cyclosporin (CyA), currently
administered in clinical practice. METHODS: A retro-
spective economic analysis was performed from a hospi-
tal perspective in Italy, Spain, and Germany. The analysis
was conducted on the ITT-population comprising 557
patients from 7 European countries. Thus, the clinical and
medical resource information for the pharmacoeconomic
analysis was pooled multi-country data, the cost data was
country speciﬁc. Costs were calculated on the actual
resources used by each patient and assigned to the treat-
ment group to which the patient was randomized. Direct
medical resource use data was costed over 6 months post
transplantation. A local health economist collected cost
information from published sources and personal inter-
views with clinicians. Costs were collected on study drug,
concomitant medication, hospitalization, dialysis, and
rejection episodes. To explore the impact of any variabil-
ity of costs, a one-way sensitivity analysis was conducted.
RESULTS: Six months after transplantation, patient sur-
vival was 99.3% (Tac) and 98.5% (CyA), p = 0.366; graft
survival was 94.6% (Tac) and 91.9% (CyA), p = 0.139.
The incidence of acute graft rejection was 32.5% (Tac)
and 51.3% (CyA), p < 0.0001. Cost-minimization analy-
sis revealed savings for tacrolimus (per patient) of
€583–1874 for surviving patients, and €781–2305 for
patients with functioning grafts. Tacrolimus was cost-
effective for patients with rejection-free grafts; savings per
patient were €4627–9919. The tacrolimus group consis-
tently had lower total costs than the cyclosporin group.
The cost advantages for tacrolimus were a result of lower
overall hospitalization costs and lower incidences of dial-
ysis and graft rejection. A sensitivity analysis regarding
the main cost drivers (hospitalization, study drug, and
concomitant medication) generally conﬁrmed the robust-
ness of this ﬁnding in all 3 countries.
URINARY/KIDNEY DISEASES OR DISORDERS—
Quality of Life Studies
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OBJECTIVE: Use of electronic data capture (EDC) in the
assessment of patient status is increasing, however it must
be determined how data collected electronically correlates
with similar data collected using the standard “paper”
method. Our objective was to compare paper and elec-
tronic administrations of a urinary voiding and symptom
diary for use in a population with benign prostatic hyper-
plasia (BPH). METHODS: Using a crossover design, men
aged 45–85 with a diagnosis of BPH and IPSS scores of
8 or greater were recruited from clinics. Subjects com-
pleted either the paper or electronic version of the diary
(depending on randomized arm) for 7 consecutive days
and then the opposing version for the following 7 con-
secutive days. Data quality was assessed for both ver-
sions. Intraclass correlation coefﬁcients (ICC) and t-test
comparisons were calculated to compare EDC and paper
versions for the mean number of urinary events, symp-
toms, and severity of urgency. Ease of use, preference, and
demographic items were also collected. RESULTS: A total
of 28 subjects were assessed with 14 in each group. Mean
age and IPSS for the total sample was 63.8 and 17.3,
respectively. Data quality concerns were minimal with
both versions. Mean differences in urinary events, symp-
toms and severity were not signiﬁcantly different (p-
values > 0.29, ICC > 0.70). Participants who took the
electronic version ﬁrst thought the paper version was con-
siderably less convenient to keep with them and more dif-
ﬁcult to use. The majority of the sample (64%) would
prefer, if given a choice, the computerized version of the
diary compared with 29% opting for the paper version
(7% indicated no real preference for either). CONCLU-
SION: As in previous studies comparing electronic to
paper assessments, this study revealed statistical evidence
to support the use of EDC of a patient urinary diary.
While some difﬁculties existed, the electronic version pro-
duced good data with low data management burden.
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